Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of DA-1241 in Healthy Men and T2DM Patients
NCT03646721Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Aug 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vanoglipel in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Dong-A ST. Primary endpoints: Adverse event at 16 weeks, 12-lead ECGs at 16 weeks and 1 more. Started Aug 2018; status: completed.
02
Drugs
vanoglipel
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03646721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646721.